Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9820308 | 0.90 | ALDH1A1 (0.46) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL1645029 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL9820277 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL8992757 | 0.84 | TSHR (0.42) | ALDH1A1TSHRTDP1MAPTLMNA | |
| SCHEMBL249846 | 0.83 | ALDH1A1 (0.68) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL30166416 | 0.82 | FBP1 (0.48) | ALDH1A1TSHRGPR35TDP1CTSD | |
| SCHEMBL6278459 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL94769 | 0.81 | GPR35 (0.55) | ALDH1A1TSHRGPR35TDP1HPGD | |
| Nitric Acid SCHEMBL9873962 | 0.80 | ALDH1A1 (0.63) | ALDH1A1TSHRGPR35TDP1HPGD | |
| SCHEMBL2416170 | 0.80 | TDP1 (0.50) | ALDH1A1TSHRGPR35TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1202801-C | Composition for dyeing keration fibres and dyeing method using same | OREAL (FR) | 2005-05-25 | — | — | CN | claimed |
| CN-1248159-A | Composition for dyeing keration fibres and dyeing method using same | OREAL (FR) | 2000-03-22 | — | — | CN | claimed |
| EP-0303826-B1 | SUBSTITUTED 2-NITRO METAPHENYLENE DIAMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING KERATINOUS FIBRES AND ESPECIALLY HUMAN HAIR | L'OREAL (FR) | 1991-02-27 | — | — | EP | claimed |
| CN-105828882-B | Packaging article comprising an envelope and an anhydrous dye composition comprising a direct dye, use thereof and process for dyeing keratin fibres | 莱雅公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-105828882-A | Packaging article comprising an envelope and an anhydrous dye composition comprising a direct dye, use thereof and process for dyeing keratin fibres | 莱雅公司 | 2016-08-03 | — | — | CN | disclosed |
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| CN-102471317-B | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH | 2014-02-26 | — | — | CN | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2074986-B1 | Process for treating hair fibres using polysiloxane/polyurea | OREAL (FR) | 2013-05-15 | — | — | EP | disclosed |
| CN-102471317-A | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH | 2012-05-23 | — | — | CN | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| CN-1394205-A | Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation | AGOURON PHARMA (US) | 2003-01-29 | — | — | CN | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
| EP-1250326-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001053268-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0303826-B1 | SUBSTITUTED 2-NITRO METAPHENYLENE DIAMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING KERATINOUS FIBRES AND ESPECIALLY HUMAN HAIR | L'OREAL (FR) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | ALDH1A1 1759/4885TSHR 2787/4885GPR35 570/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | ALDH1A1 1759/4885TSHR 2787/4885GPR35 570/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | ALDH1A1 1759/4885TSHR 2787/4885GPR35 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.